Advocates shared their stories and projects at the AACR Annual Meeting.
by Kate Yandell
National Cancer Institute director Norman “Ned” Sharpless meets with advocates and outlines areas of focus for the agency.
by Marci A. Landsmann
The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.
by Kevin McLaughlin
Panel of experts discuss survivorship challenges and potential areas for study.
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors’ molecular characteristics, not to their tissues of origin.
Cancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.
AACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.
Two graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.
by Bob Riter and Carole Baas
Policy Matters
A judge orders tobacco companies to come clean about the dangers of their products after decades of deception.
by Roy S. Herbst, MD, PhD
Forward Look
CBS, ABC and NBC are airing advertisements that acknowledge the link between cigarettes and cancer.
by Sue Rochman
In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.
To increase efficacy and combat resistance to checkpoint inhibitors, many clinical trials are centered on combining an immune checkpoint inhibitor with a second drug.
The FDA expands use of durvalumab to non–small cell lung cancer.
A collaborative initiative seeks to improve understanding of cancer outcomes in African-American patients through genomic sequencing.
The Financial Toll of Cancer
donate to the AACR